The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
Multiparametric magnetic resonance imaging is highly accurate in differentiating nonmuscle-invasive from muscle-invasive bladder cancer, according to a new systematic review and meta-analysis.
Recent research suggests cancer patients who have undergone genetic testing for inherited or acquired mutations were more likely to have prolonged overall survival than patients who did not,
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Template-based lymph node dissection in patients with upper tract urothelial carcinoma could facilitate better local disease control by eliminating micrometastasis, according to investigators.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
